Mohammed Najeeb Al Hallak, M.D., MS

Specialties

Oncology - Medical

Board Certification

American Board of Internal Medicine, Medical Oncology and Hematology

Language(s) Spoken

Arabic, English

Locations

Karmanos Cancer Center
4100 John R
Detroit, MI 48313
Get Directions

Phone:1-800-KARMANOS

Call For Appointment

Watch Video

Podcast: Listen

Locations

Karmanos Cancer Center

4100 John R
Detroit, MI 48313
Get Directions

Phone:1-800-KARMANOS

Get Directions

Get Directions

Education

Additional Info

About

Dr. Al Hallak has a broad background in medicine, with specialized training in oncology. He has profound clinical expertise in managing Gastrointestinal (GI) malignancies, in particular, pancreatic cancer. Additionally, Dr. Al Hallak has a robust clinical research training provided by the University of Michigan Master of Science program in clinical research design and statistical analysis, as well as a solid basic science training at Karmanos Cancer Institute.

His research focus is in gastrointestinal malignancies, specifically pancreatic cancer. The goal of his research is to better understand the molecular biology and microenvironment of GI cancers, discover new treatments and prevent treatment-induced toxicities. He is able to translate passion for improving treatment outcomes for GI cancer patients via conducting clinical trials (phase I-III), investigator-initiated and pharma-sponsored. Dr. Hallak works through translational research to identify new biomarkers that help to individualize the treatment choice for patients and provide them with an accurate prediction of the treatment effect as well as a prognosis of their cancer. He is leading the initiative to start a postmortem rapid autopsy program for pancreatic cancer patients in Detroit. Additionally, he is a co-principal investigator on our Translational Pilot Trial to study the role of different microRNAs in predicting response and resistance to Gemcitabine and Nab-Paclitaxel when used as first-line therapy for metastatic or locally advanced unresectable Pancreatic cancer patients. He is also a co-leader for the Phase II Clinical Trial to study the effect of adding XPO1 inhibitor (Selinexor) to Gemcitabine as a second-line treatment for patients with metastatic or locally advanced unresectable pancreatic cancer patients after non-Gemcitabine regimen failure.

Related News

December 18, 2024
Karmanos Cancer Institute Physicians Begin Prescribing New FDA-approved Radiofrequency Electromagnetic Device to Treat Advanced Liver Cancer

The Barbara Ann Karmanos Cancer Institute , the largest provider of cancer care and research in Michigan and part of McLaren Health Care, announced today that the new TheraBionic P1 device, an FDA-approved, at-home treatment , is now available to treat advanced liver cancer. Karmanos Cancer Center is the first institution worldwide to prescribe this treatment. The TheraBionic P1 device is a novel, handheld, portable device that produces low levels of 27.12 MHz radiofrequency electromagnetic fields, whic...
Read More
November 05, 2024
Karmanos Cancer Institute Recognizes Pancreatic Cancer Awareness Month, the Third Deadliest Cancer

The Barbara Ann Karmanos Cancer Institute , cancer centers, and other organizations nationwide recognize November as Pancreatic Cancer Awareness Month. As its name indicates, pancreatic cancer originates in the pancreas, an organ that sits behind the stomach. The pancreas aids in digestion and helps regulate blood sugar. About Pancreatic Cancer Exocrine cells make up much of the pancreas. When these cells grow out of control, adenocarcinoma of the pancreas occurs. Pancreatic adenocarcinomas account for ...
Read More
October 15, 2024
Karmanos Faculty Honored at Annual WSU School of Medicine Faculty Awards and Promotion and Tenure Ceremony

The Office of Faculty Affairs and Professional Development at Wayne State University’s (WSU) School of Medicine held its 2024 School of Medicine Faculty Awards and Promotion and Tenure Ceremony on Sept. 26. This is an annual recognition of faculty who have made outstanding contributions to teaching, mentoring, research, and leadership. This year, several Barbara Ann Karmanos Cancer Institute faculty, researchers and medical staff at the Karmanos Cancer Center received these awards, highlighting their si...
Read More

Provider Profile:
Mohammed Najeeb Al Hallak, M.D., MS